A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Trial Profile

A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Azilsartan medoxomil/chlortalidone (Primary) ; Olmesartan medoxomil/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2013 Pooled analysis presented at the 23rd European Meeting on Hypertension.
    • 18 Jun 2012 Results published in Hypertension.
    • 23 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension (ASH-2011).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top